You can read the full article at LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept: Cell Metabolism
Better body composition: Losing 30 lbs of fat while maintaining muscle looks completely different from losing 20 lbs of fat plus 10 lbs of muscle
CrossRef Distinct tumor immune microenvironment modulation by anti-PD-1/PD-L1, VEGF, and CTLA-4 blockade provides a rationale for triplet therapy in hepatocellular carcinoma Hideki Iwamoto, Hironori Koga, Takumi Kawaguchi Clinical and Molecular Hepatology .2026
Regul Pept 2008
In 2022, total Medicare expenditures on the GLP-1/GIP agonists were $5.7 billion
Why They Matter for Fat Loss Growth hormone influences: Lipolysis Fat oxidation Lean mass preservation In research contexts, secretagogues are often explored for their ability to: Improve body composition Support muscle retention during caloric deficit Enhance recovery A GHRH analogue such as CJC-1295 may be studied alongside multi-agonist compounds in body composition protocols to mitigate lean mass reduction during aggressive fat loss phases
%20(1).png)
